Clinical trial
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
NCT00114738 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00114738 |
|---|---|
| Title | EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma |
| Official title | Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib (EPOCH-R-B) Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Mantle Cell, Mantle Cell Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | Rituximab (R), EPOCH, Bortezomib (B), Bortezomib, Bortezomib or observation |
| Enrollment | 53 |
| Start date | Jun 15, 2005 |
| Primary completion | Aug 11, 2016 |
| Completion | Aug 11, 2022 |
| First posted | Jun 17, 2005 |
| Last update posted | Oct 10, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: